Association Between Atopic Dermatitis and Major Cardiovascular Outcomes: a Two-Sample Mendelian Randomization Study

Hongjiao Qi¹, Lifeng Wang², Linfeng Li¹

1 Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, PR China
2 Department of Dermatology, Beijing Luhe Hospital, Capital Medical university, Beijing, PR China

Key words: atopic dermatitis, cardiovascular disease, Mendelian randomization

Citation: Qi H, Wang L, Li L. Association between Atopic Dermatitis and Major Cardiovascular Outcomes: A Two-Sample Mendelian Randomization Study. Dermatol Pract Concept. 2022;12(4):e2022165. DOI: https://doi.org/10.5826/dpc.1204a165

Accepted: February 28, 2022; Published: October 2022

Copyright: ©2022 Qi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: None.

Authorship: All authors have contributed significantly to this publication.

Corresponding author: Linfeng Li, Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, PR China, Address: 95 Yong’an Road, Xicheng District, Beijing, China. Zip: 100050, Tel: +8613693620186, E-mail: zoonli@sina.com

ABSTRACT

Introduction: Atopic dermatitis (AD) has been linked to cardiovascular disease (CVD) in population-based studies, however, their causal relationship is still unclear.

Objectives: To evaluate the causal association of AD with risk of cardiovascular outcomes using a Mendelian randomization (MR) approach.

Methods: We extracted summary-level data for AD, stroke, heart failure, coronary artery disease (CAD), myocardial infarction, angina pectoris from published, nonoverlapping genome-wide association studies (GWAS). Inverse variance weighted (IVW) method was used as the primary analysis. Alternative methods, including weighted median, MR Egger, MR-Pleiotropy Residual Sum and Outlier, weighted mode, and leave-out analysis, were performed to examine potential pleiotropy.

Results: Thirteen SNPs (13,287 cases and 41,345 controls) were selected as instrumental variables (IVs). No associations of AD with risks of stroke (odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.97-1.09, P = 0.3630), heart failure (OR = 1.04, 95%CI: 0.99-1.09, P= 0.119), coronary artery disease (OR = 1.00, 95%CI: 0.96-1.05, P = 0.988), myocardial infarction (OR = 1.00, 95%CI: 1.00-1.00, P = 0.322), and angina pectoris (OR = 1.00, 95%CI: 1.00-1.00, P = 0.369) was found. No significant effect of pleiotropy was detected.

Conclusions: This MR study does not support a causal effect of AD on stroke, heart failure, CAD, myocardial infarction, angina pectoris.
Introduction

Atopic dermatitis (AD, atopic eczema, eczema) is a common chronic, inflammatory, relapsing, skin diseases [1]. The prevalence of AD is 15 to 20% among children and 7% to 14% among adults [2,3]. It is characterized by eczematous lesions, varying degrees of pruritus, and a chronic or relapsing disease course [4]. AD broadly decreases health-related quality of life [5].

Recently, there has been a growing interest in the putative cardiovascular comorbidities of AD in population-based observational studies [6-11]. However, owing to the nature of being susceptible to potential confounders and reverse causation in observational study design [12], it remains unclear whether the elevated risk of CVD in patients with AD is caused by AD or introduced by confounding factors of AD and CVD. Understanding the causal relationship between AD and CVD could have implications for appropriate identification, clinical surveillance, and management of high-risk population.

Mendelian randomization (MR) analysis is a novel epidemiological approach to assess the causal relationship between an exposure and an outcome [12], with less susceptibility to unmeasured confounders and reverse causation by using genetic variants (i.e., single nucleotide polymorphisms, SNPs) as instrumental variables (IVs) [13,14].

Objectives

In this study, we explored the causal associations between AD and CVD events using the MR method.

Methods

We carried out a two-sample MR analysis based on summary statistics to investigate the causal relationship between AD and CVD events including stroke, heart failure, CAD, myocardial infarction, and angina pectoris. Single nucleotide polymorphisms (SNPs) were selected as instruments variables because they are randomly allocated and less probable to be affected by confounding or reverse causation [13,14]. We used publicly available data, informed patients consents and ethical approvals were available in original genome-wide association studies (GWAS) studies.

Data Sources and Selection of SNPs

Summary-level data for AD were extracted from the EArl Genetics and Lifecourse Epidemiology (EAGLE) eczema consortium, including 13,287 cases and 41,345 controls of mostly European ancestry [16]. Summary-level data stroke were extracted from the MEGASTROKE Consortium, a meta-analysis of 29 GWAS including a total of 40,585 cases and 406,111 non-cases of European ancestry [17]. Summary-level data for heart failure were extracted from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium [18], comprising 47,309 cases and 930,014 non-cases of European ancestry across 26 studies. Summary-level data for CAD from UKBiobank-CardioMetabolic-Consortium CHD working group included 10801 cases and 137914 non-cases of European ancestry [19]. Summary-level data for myocardial infarction from UKBiobank included 4837 cases and 332,362 non-cases of European ancestry. Summary-level data for angina pectoris from UKBiobank included 4,837 cases and 332,362 non-cases of European ancestry.

Statistical Analysis

For each CVD outcome, we carried out two-sample MR analysis to estimate the causal effect of AD, using the “TwoSampleMR” package of R. The inverse-variance weighted (IVW) linear regression was conducted as the primary analysis. IVW is an efficient analysis method which assumes that all genetic variants are valid IVs, and that there is no horizontal pleiotropy [20]. We calculated the odds ratio (OR) with 95% confidence interval (CI) and created the SNP effect scatter plot. Besides, we assessed the potential violations of the assumptions of MR analysis by performing a number of complimentary sensitivity analysis: weighted median approach for examining result robustness when some instruments may be potentially invalid [20], MR-Egger regression for evaluating the directional pleiotropy of instruments [21,22], weighted mode, which generally has low bias and low Type I error rate inflation [23], MR Pleiotropy RESidual Sum and Outlier (MR PRESSO) for outlier instrument detection [24], and leave-one-out analysis to evaluate whether the MR estimate was influenced by single proxy SNP. We also calculated the Cochran Q test from the IVW analysis to examine potential horizontal pleiotropy.

All statistical analyses were performed using R software 4.0.3 (R Foundation for Statistical Computing). All statistical tests were two-sided with \( \alpha = 0.05 \).

Results

Genetic Instruments

Thirteen SNPs were identified as associated with AD (\( P<5\times10^{-8} \)), with independent inheritance (\( r^2<0.01 \), and without linkage disequilibrium (LD) in summary statistics. All of these 13 SNPs were available in GWAS for stroke, heart failure, CAD, myocardial infarction, angina pectoris. Details of the included SNPs are shown in Tables S1, Tables S2, S3, S4, and S5 respectively.
Two-sample MR of AD and CVD

No significant evidence was found for a causal effect of AD on stroke, heart failure, CAD, myocardial infarction, angina pectoris using the IVW analysis (stroke: OR = 1.03, 95% CI: 0.97-1.09, P = 0.363; heart failure: OR = 1.04, 95% CI: 0.99-1.09, P = 0.119; CAD: OR = 1.00, 95% CI: 0.94-1.06, P = 0.961; myocardial infarction: OR = 1.00, 95% CI: 1.00-1.00, P = 0.322; angina pectoris: OR = 1.00, 95% CI: 1.00-1.00, P = 0.369). The results neither weighted median, MR Egger, weighted mode nor MR PRESSO analyses were significant for all of the diseases above (Table 1 and Figures S1, S2, S3, S4, S5).

Leave-one-out analysis indicated no influence of single SNP on the risk estimates of AD on stroke, heart failure, CAD, myocardial infarction, angina pectoris. P values of Cochrane Q test and MR Egger intercept for AD on stroke were 0.481 and 0.695, respectively; for AD on heart failure were 0.150 and 0.224, respectively; for AD on CAD were 0.146 and 0.583, respectively; for AD on myocardial infarction were 0.417 and 0.993, respectively; for AD on angina pectoris were 0.080 and 0.752, respectively, suggesting no evidence of potential horizontal pleiotropy and heterogeneity.

Conclusions

To the best of our knowledge, this is the first study to explore the causal relationship between AD and CVD based on an MR approach. Our results did not support a causal effect of AD on CVD.

Previous studies on the link between AD and stroke are controversial. In a Danish matched cohort study, patients with severe AD had an increased risk of ischemic stroke, but after adjustment for socioeconomic status, smoking, comorbidities, and medication use, the risk was similar with controls [6]. In a cohort from the Nurses’ Health Study 2, the risk of stroke was significantly increased in female nurses with AD in the age and models adjusted for demographic, lifestyle risk factors, family history of MI, and

Table 1. The Causal Effect of Atopic Dermatitis on Stroke

| Type of CVD          | Method         | OR (95% CI)       | P Value | No. of SNPs |
|----------------------|----------------|-------------------|---------|-------------|
| Stroke               | IVW            | 1.03 (0.97-1.09)  | 0.363   | 13          |
|                      | Weighted median| 0.99 (0.92-1.05)  | 0.681   | 13          |
|                      | MR Egger       | 0.96 (0.79-1.17)  | 0.694   | 13          |
|                      | Weighted mode  | 0.97 (0.88-1.07)  | 0.529   | 13          |
|                      | MR PRESSO      | 1.01 (0.96-1.06)  | 0.659   | 13          |
| Heart failure        | IVW            | 1.04 (0.99-1.09)  | 0.119   | 13          |
|                      | Weighted median| 1.05 (1.00-1.11)  | 0.069   | 13          |
|                      | MR Egger       | 1.13 (0.98-1.30)  | 0.110   | 13          |
|                      | Weighted mode  | 1.06 (0.98-1.14)  | 0.176   | 13          |
|                      | MR PRESSO      | 1.04 (0.99-1.09)  | 0.145   | 13          |
| Coronary artery disease | IVW         | 1.00 (0.96-1.05)  | 0.988   | 13          |
|                      | Weighted median| 0.99 (0.94-1.05)  | 0.760   | 13          |
|                      | MR Egger       | 0.96 (0.84-1.10)  | 0.608   | 13          |
|                      | Weighted mode  | 0.98 (0.90-1.07)  | 0.654   | 13          |
|                      | MR PRESSO      | 1.00 (0.96-1.05)  | 0.988   | 13          |
| Myocardial infarction | IVW            | 1.00 (1.00-1.00)  | 0.322   | 13          |
|                      | Weighted median| 1.01 (1.00-1.00)  | 0.789   | 13          |
|                      | MR Egger       | 1.00 (1.00-1.00)  | 0.724   | 13          |
|                      | Weighted mode  | 1.00 (1.00-1.00)  | 0.574   | 13          |
|                      | MR PRESSO      | 1.00 (1.00-1.00)  | 0.328   | 13          |
| Angina pectoris      | IVW            | 1.00 (1.00-1.00)  | 0.369   | 13          |
|                      | Weighted median| 1.01 (1.00-1.00)  | 0.416   | 13          |
|                      | MR Egger       | 1.00 (1.00-1.00)  | 0.992   | 13          |
|                      | Weighted mode  | 1.00 (1.00-1.00)  | 0.627   | 13          |
|                      | MR PRESSO      | 1.00 (1.00-1.00)  | 0.386   | 13          |

CI = Confidence interval; CVD = cardiovascular disease; IVW = inverse variance-weighted; MR = mendelian randomization; OR = odds ratio; SNP = single-nucleotide polymorphism.
postmenopausal hormone replacement use. However, after further controlling for hypertension, hypercholesterolemia, and diabetes, the association between AD and stroke was no longer significant [7]. In a Swedish nationwide case-control study, only severe AD was associated with ischemic stroke [8]. A cross-sectional study conducted among primary care and community settings patients found only adult patients with moderate to severe AD was significantly associated with higher prevalence rates of prior stroke compared to the control: 4.4% versus 2.4% [25]. In a large population-based study including three surveys in US, AD was not associated with stroke in NHANES 2005-2006, but was significantly associated with higher odds of stroke in NHIS 2010 and 2012 in crude models and multivariate models adjusted for demographic, lifestyle factors, hay fever and asthma [9]. A population-based cohort study with data from the UK Clinical Practice Research Datalink reported very modest association between AD and stroke in adjusted models, and the associations were considerably stronger in patients with severe or active AD [10]. Two recent large German studies also found no association between AD and stroke [26,27]. Moreover, a large Canadian cohort even found AD was associated with lower risk of stroke in adjusted model [28].

Though there are only few studies on the link between AD and heart failure, the results are still inconsistent. An US cross-sectional inpatient study reported a significant relationship between AD and heart failure [29]. A cohort study also found positive association between AD and heart failure [10].

CAD is a cause of major morbidity and mortality worldwide. It includes stable ischemic heart disease, MI and unstable angina [30]. Several studies provided estimates for the association of AD with the risk of CAD. The abovementioned study conducted by Silverberg et al. showed AD was associated with significantly higher odds of CAD, the associations attenuated but remained significant in the three adjusted models [9]. But Kwa et al. study reported AD was not significantly associated with CAD [29]. Findings about associations between AD and angina were also mixing. Standl et al. and Silverwood et al. reported a significantly positive association between AD and angina [10,26]. However, AD was not found to be significantly associated with angina in NHANES [9]. The situation is similar to MI. There is a significant association between AD and MI in NHANES, but after controlling risk factor of CVD, the association did not remain significant [9]. Studies of Drucker et al. and Standl et al. also suggested no evidence of the association between AD and MI [7,26,28]. However, Silverwood et al., the NHIS 2010, and a recent cross-sectional study suggested AD was associated with an increased risk of MI, even adjusted for potential confounding factors [9,10,31]. AD and CVD related studies are shown in Table S6.

There are some limitations to the present study. First, the summary-level GWAS data we used were based mainly on people of European ancestry. Therefore, results in this study may not be applicable to other populations. Second, onset age and disease severity of AD might influence the association between AD and comorbidities, but because the limitation of data, we were not able to perform subgroup analyses by age and severity of AD. Third, an important limitation for MR study is potential pleiotropy. In this study, we applied various MR approaches to test for potential pleiotropy, and no evidence of pleiotropy for all the analyses was observed. Moreover, the definitions of AD and comorbidities used in the data is a mixture of self-reported diagnosis together with doctor diagnosed cases, which may cause bias to our findings.

**Conclusion**

In conclusion, MR study does not support a causal effect of AD on stroke, heart failure, CAD, myocardial infarction, angina pectoris.

**References**

1. Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. *Ann Allergy Asthma Immunol.* 2021;126(1):21–31. DOI: 10.1016/j.anai.2020.08.016. PMID: 32818591.

2. Bylund S, von Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. *Acta Derm Venereol.* 2020;100(12):adv00160. DOI:10.2340/00015555–3510. PMID: 32412646.

3. Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. *Clin Dermatol.* 2018;36(5):595–605. DOI: 10.1016/j.clindermatol.2018.05.007. PMID: 30217272.

4. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet.* 2020;396(10247):345–360. DOI:10.1016/s0140-6736(20)31286–1. PMID: 32738956.

5. Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. *J Invest Dermatol.* 2017 Jan;137(1):26–30. DOI: 10.1016/j.jid.2016.07.012. PMID: 27616422.

6. Andersen YMF, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. *J Allergy Clin Immunol.* 2016;138(1):310–312.e3. DOI: 10.1016/j.jaci.2016.01.015. PMID: 26971689.

7. Drucker AM, Li WQ, Cho E, et al. Atopic dermatitis is not independently associated with nonfatal myocardial infarction or stroke among US women. *Allergy.* 2016;71(10):1496–1500. DOI:10.1111/all.12957. PMID: 27291834. PMCID: PMC5023476.

8. Ivert LU, Johansson EK, Dal H, Lindelof B, Wahlgren C-F, Bradley M. Association Between Atopic Dermatitis and Cardiovascular Disease: A Nationwide Register-based Case-control Study from Sweden. *Acta Derm Venereol.* 2019;99(10):865–870. DOI: 10.2340/00015555–3235. PMID: 31197387.
10. Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018;361:k1786. DOI: 10.1136/bmj.k1786. PMID: 29792314. PMCID: PMC6190010.

11. Jung HJ, Lee DH, Park MY, Ahn J. Cardiovascular comorbidities of atopic dermatitis: using National Health Insurance data in Korea. Allergy Asthma Clin Immunol. 2021;17(1):94. DOI: 10.1186/s13232-021-00590-x. PMID: 34551806. PMCID: PMC8456522.

12. Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22. DOI: 10.1093/ije/dyg070. PMID: 12689998.

13. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–1163. DOI:10.1002/sim.3034. PMID: 1786233.

14. Kattikireddi SV, Green MJ, Taylor AE, Davey Smith G, Munafò MR. Assessing causal relationships using genetic proxies for exposures: an introduction to Mendelian randomization. Addiction. 2018;113(4):764–774. DOI: 10.1111/add.14038. PMID: 28921935. PMCID: PMC5873430.

15. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res. 2007;16(4):309–330. DOI: 10.1177/0962280206077743. PMID: 17715159.

16. Paternoster L, Standl M, Waage J, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449–1456. DOI:10.1038/ng.3424. PMID: 26482879. PMCID: PMC4753676.

17. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50(4):524–537. DOI:10.1038/s41588-018-0058-3. PMID: 29531354. PMCID: PMC6968830.

18. Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian randomization analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11(1):163. DOI:10.1038/s41467-019-13690-5. PMID: 31919418. PMCID: PMC6952380.

19. Nelson CP, Goel A, Butterworth AS, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nat Genet. 2017;49(9):1385–1391. DOI: 10.1038/ng.3913. PMID: 28714975.

20. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304–314. DOI:10.1002/gepi.21965. PMID: 27061298. PMCID: PMC4849733.

21. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 2016;45(6):1961–1974. DOI: 10.1093/ije/dyw220. PMID: 27616674. PMCID: PMC5446088.

22. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377–389. DOI:10.1007/s10654-017-0255-x. PMID: 28527048. PMCID: PMC5506233.

23. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11(1):376. DOI:10.1038/s41467-019-14156-4. PMID: 31953392. PMCID: PMC6969055.

24. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–698. DOI:10.1038/s41588-018-0099-7. PMID: 29686387. PMCID: PMC6083387.

25. Shalom G, Dreijer J, Kridin K, et al. Atopic dermatitis and the metabolic syndrome: a cross-sectional study of 116 816 patients. J Eur Acad Dermatol Venereol. 2019;33(9):1762–1767. DOI: 10.1111/jdv.15642. PMID: 31045273.

26. Standl M, Tesch F, Baurecht H, et al. Association of Atopic Dermatitis with Cardiovascular Risk Factors and Diseases. J Invest Dermatol. 2017;137(5):1074–1081. DOI: 10.1016/j.jid.2016.11.031. PMID: 28011146.

27. Treudler R, Zeynalova S, Walther F, Engel C, Simon JC. Atopic dermatitis is associated with autoimmune but not with cardiovascular comorbidities in a random sample of the general population in Leipzig, Germany. J Eur Acad Dermatol Venereol. 2018;32(2):e44–e46. DOI: 10.1111/jdv.14495. PMID: 28758257.

28. Drucker AM, Qureshi AA, Dummer TJB, Parker L, Li WQ. Atopic dermatitis and risk of hypertension, type 2 diabetes, myocardial infarction and stroke in a cross-sectional analysis from the Canadian Partnership for Tomorrow Project. Br J Dermatol. 2017;177(4):1043–1051. DOI: 10.1111/bjd.15727. PMID: 28617976.

29. Kwa MC, Silverberg JL. Association Between Inflammatory Skin Disease and Cardiovascular and Cerebrovascular Co-Morbidities in US Adults: Analysis of Nationwide Inpatient Sample Data. Am J Clin Dermatol. 2017;18(6):813–823. DOI: 10.1007/s40257-017-0293-x. PMID: 28534318.

30. Shahjehan RD, Bhutta BS. Coronary Artery Disease. 2022 Feb 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 33231974.

31. Rhee T-M, Choi E-K, Han K-D, Lee S-R, Oh S. Impact of the combinations of allergic diseases on myocardial infarction and mortality. J Allergy Clin Immunol Pract. 2021;9(2):872–880.e4. DOI: 10.1016/j.jaip.2020.09.008. PMID: 3296131.
## Supplementary File

### Table 1. Leave Out Analysis for the Association Between AD and Stroke.

| SNP            | OR     | lci    | uci    | p      |
|----------------|--------|--------|--------|--------|
| rs10790275     | 1.0366 | 0.9728 | 1.1046 | 0.2674 |
| rs12144049     | 1.0424 | 0.9727 | 1.1171 | 0.2392 |
| rs12188917     | 1.0419 | 0.9784 | 1.1096 | 0.2001 |
| rs12334935     | 1.0351 | 0.9707 | 1.1038 | 0.2919 |
| rs2212434      | 1.0200 | 0.9552 | 1.0891 | 0.5540 |
| rs2477121      | 1.0341 | 0.9693 | 1.1032 | 0.3088 |
| rs2918299      | 1.0318 | 0.9654 | 1.1017 | 0.3598 |
| rs4151657      | 1.0223 | 0.9596 | 1.0891 | 0.4940 |
| rs479844       | 1.0163 | 0.9523 | 1.0845 | 0.6260 |
| rs6062486      | 1.0118 | 0.9619 | 1.0641 | 0.6498 |
| rs61815704     | 1.0309 | 0.9637 | 1.1027 | 0.3757 |
| rs6419573      | 1.0319 | 0.9660 | 1.1023 | 0.3504 |
| rs8066625      | 1.0241 | 0.9529 | 1.0933 | 0.4750 |
| All            | 1.0290 | 0.9674 | 1.0945 | 0.3633 |

OR: odds ratio; lcl: lower confidence intervals; ucl: upper confidence intervals

### Table 2. Leave Out Analysis for the Association Between AD and Heart Failure.

| SNP            | OR     | lci    | uci    | p      |
|----------------|--------|--------|--------|--------|
| rs10790275     | 1.0457 | 0.9983 | 1.0952 | 0.0585 |
| rs12144049     | 1.0406 | 0.9858 | 1.0983 | 0.1489 |
| rs12188917     | 1.0399 | 0.9853 | 1.0930 | 0.1223 |
| rs12334935     | 1.0491 | 1.0067 | 1.0932 | 0.0226 |
| rs2212434      | 1.0297 | 0.9802 | 1.0816 | 0.2433 |
| rs2477121      | 1.0457 | 0.9984 | 1.0952 | 0.0581 |
| rs2918299      | 1.0362 | 0.9854 | 1.0895 | 0.1649 |
| rs4151657      | 1.0319 | 0.9837 | 1.0824 | 0.1977 |
| rs479844       | 1.0284 | 0.9785 | 1.0809 | 0.2684 |
| rs6062486      | 1.0413 | 0.9912 | 1.0941 | 0.1077 |
| rs61815704     | 1.0358 | 0.9844 | 1.0899 | 0.1754 |
| rs6419573      | 1.0374 | 0.9873 | 1.0900 | 0.1452 |
| rs8066625      | 1.0286 | 0.9818 | 1.0776 | 0.2348 |
| All            | 1.0377 | 0.9905 | 1.0873 | 0.1186 |

OR: odds ratio; lcl: lower confidence intervals; ucl: upper confidence intervals
### Table 3. Leave Out Analysis for the Association Between AD and Coronary Artery Disease.

| SNP          | OR     | lci     | uci     | p       |
|--------------|--------|---------|---------|---------|
| rs10790275   | 0.998822 | 0.953129 | 1.046706 | 0.960658 |
| rs12144049   | 0.999948 | 0.950616 | 1.05184  | 0.998389 |
| rs12188917   | 0.994383 | 0.948679 | 1.042289 | 0.814494 |
| rs12334935   | 1.005797 | 0.962038 | 1.051546 | 0.798973 |
| rs2212434    | 1.009113 | 0.964813 | 1.055448 | 0.692053 |
| rs2477121    | 1.001785 | 0.95586  | 1.049915 | 0.940634 |
| rs2918299    | 1.003518 | 0.957882 | 1.051329 | 0.88243  |
| rs4151657    | 0.988936 | 0.951483 | 1.027864 | 0.572203 |
| rs479844     | 0.98138  | 0.946092 | 1.032053 | 0.596611 |
| rs6062486    | 1.002905 | 0.957254 | 1.050733 | 0.902869 |
| rs61815704   | 1.008962 | 0.963617 | 1.056441 | 0.703724 |
| rs6419573    | 0.999903 | 0.953663 | 1.048385 | 0.996795 |
| rs8066625    | 1.002174 | 0.956419 | 1.050117 | 0.927441 |
| All          | 1.000338 | 0.957371 | 1.045233 | 0.987967 |

OR: odds ratio; lcl: lower confidence intervals; ucl: upper confidence intervals

### Table 4. Leave Out Analysis for the Association Between AD and Myocardial Infarction.

| SNP          | OR     | lci     | uci     | p       |
|--------------|--------|---------|---------|---------|
| rs10790275   | 0.999032 | 0.997552 | 1.000513 | 0.199932 |
| rs12144049   | 0.99909  | 0.997501 | 1.000681 | 0.262249 |
| rs12188917   | 0.999546 | 0.998032 | 1.001061 | 0.556637 |
| rs12334935   | 0.999523 | 0.998046 | 1.001002 | 0.527093 |
| rs2212434    | 0.999239 | 0.997709 | 1.000772 | 0.330301 |
| rs2477121    | 0.999383 | 0.997902 | 1.000866 | 0.414595 |
| rs2918299    | 0.999211 | 0.997712 | 1.000712 | 0.302782 |
| rs4151657    | 0.999099 | 0.997621 | 1.00058  | 0.232923 |
| rs479844     | 0.999167 | 0.997629 | 1.000707 | 0.288732 |
| rs6062486    | 0.999378 | 0.997897 | 1.000862 | 0.411388 |
| rs61815704   | 0.999544 | 0.997987 | 1.001104 | 0.566673 |
| rs6419573    | 0.999325 | 0.997826 | 1.000827 | 0.378057 |
| rs8066625    | 0.998984 | 0.997499 | 1.00047  | 0.180141 |
| All          | 0.99927  | 0.997827 | 1.000716 | 0.322364 |

OR: odds ratio; lcl: lower confidence intervals; ucl: upper confidence intervals
Table 5. Leave Out Analysis for the Association Between AD and Angina Pectoris.

| SNP           | OR     | lci     | uci     | p       |
|---------------|--------|---------|---------|---------|
| rs10790275    | 1.000954 | 0.999344 | 1.002566 | 0.245799 |
| rs12144049    | 1.001062 | 0.999283 | 1.002844 | 0.242133 |
| rs12188917    | 1.000588 | 0.998863 | 1.002316 | 0.504061 |
| rs12334935    | 1.001026 | 0.999524 | 1.00253 | 0.180897 |
| rs2212434     | 1.000258 | 0.998796 | 1.001722 | 0.729742 |
| rs2477121     | 1.000653 | 0.998952 | 1.002356 | 0.452234 |
| rs2918299     | 1.000854 | 0.999161 | 1.002551 | 0.323015 |
| rs4151657     | 1.00054 | 0.998912 | 1.00217 | 0.51587 |
| rs479844      | 1.000581 | 0.998834 | 1.002331 | 0.514699 |
| rs6062486     | 1.000607 | 0.998924 | 1.002292 | 0.480047 |
| rs61815704    | 1.000857 | 0.999064 | 1.002653 | 0.349097 |
| rs6419573     | 1.000952 | 0.99932 | 1.002587 | 0.253258 |
| rs8066625     | 1.00064 | 0.998937 | 1.002347 | 0.461454 |
| All           | 1.000735 | 0.999134 | 1.002338 | 0.368553 |

OR: odds ratio; lcl: lower confidence intervals; ucl: upper confidence intervals
### Table 6: Characteristics of Population-Based Studies Reporting the Association Between AD and CVD

| Study | Study design and Period | Setting | Age, sample size (proportion of males) | Diagnosis of AD | Outcome definition | Statistical analysis | CAD | Angina | MI | HF | Stroke |
|-------|-------------------------|---------|----------------------------------------|-----------------|-------------------|---------------------|-----|--------|----|----|--------|
| Andersen, 2016 | Cohort, (1997-2012) | Denmark | ≥15 yrs, Mild: 26.89%, Severe: 2.527 (46.1%), Control: 145372 | Hospital diagnosis of AD, ICD-8, ICD-10 codes | ICD-8, ICD-10 codes | Poisson regression | Adjusted IRR: Mild: 0.82 (0.66-1.02), Severe: 1.39 (0.95-2.03); Fully adjusted IRR Mild: 0.73 (0.59-0.91), Severe: 1.06 (0.72-1.56) | Adjusted IRR: Mild 0.92 (0.78-1.11), Severe: 1.51 (1.08-2.10); Fully adjusted IRR Mild: 0.82 (0.68-0.98), Severe: 1.19 (0.85-1.65) |
| Drucker, 2016 | Cross-sectional, (1989-2009) | USA | Total: 78702, AD: 7916 (0%) | Self-reported clinician diagnosed eczema (AD) | Self-reported, confirmed by medical record, letter or interview | Logistic regression | Adjusted OR: 0.97 (0.69-1.36); MV-adjusted OR 0.94 (0.67-1.32); MV-adjusted OR 0.91 (0.65-1.28) | Adjusted OR: 1.38 (1.03-1.85); MV-adjusted OR 1.35 (1.00-1.80); MV-adjusted OR 1.31 (0.98-1.76) |
| Drucker, 2017 | Cross-sectional, (2009 onwards) | Canada | 30-74 yrs, Total: 259119, AD: 21379 (25%) | Self-reported a diagnosis of eczema | Self-reported a diagnosis of MI, stroke | Logistic regression | Adjusted OR: 0.83 (0.72-0.95); MV-adjusted model 1 OR: 0.80 (0.69-0.92); MV-adjusted model 2 OR: 0.87 (0.75-1.00) | Adjusted OR: 0.81 (0.68-0.97); MV-adjusted model 1 OR: 0.75 (0.62-0.89); MV-adjusted model 2 OR: 0.79 (0.66-0.95) |
| Egeberg, 2016 | Cross-sectional, (1995-2012) | Denmark | ≥18 yrs, AD: 7937 (38.2%), Control: 79370 | Clinical diagnosis of AD ICD-10 codes | Administrative code | Logistic regression | Adjusted OR: overall: 1.1 (0.92-1.33); mild: 0.88 (0.63-1.23); severe: 1.23 (0.98-1.54) | Adjusted OR: overall: 1.32 (1.32-1.74); mild: 1.23 (0.94-1.60); severe: 1.45 (1.19-1.77) |
| Time Period          | Country | Age | AD (cases) | Non-severe (cases) | Severe (cases) | Control (cases) | ICD codes | Conditional logistic regression |
|---------------------|---------|-----|------------|-------------------|---------------|----------------|------------|--------------------------------|
| Ivert, 2019<a>     | Case-control, (1968 -2016) | ≥15 yrs, | AD: 104832, Non-severe: 95274 (33.8%), Severe: 9558 (35.7%), Control: 1022435 | | | | | |
|                     | Sweden  |     |            |                   |               |                | ICD-8: ICD-9: ICD-10: codes | | |
|                     |         |     |            |                   |               |                |            | All cases: all crude<sup>10</sup> OR: 1.18 (1.13-1.23), all fully adjusted<sup>11</sup> OR: 1.13 (1.08-1.19), Men crude<sup>1</sup> OR: 1.15 (1.08-1.22), Men fully adjusted<sup>1</sup> OR: 1.10 (1.03-1.18), Women crude<sup>1</sup> OR: 1.21 (1.14-1.28), Women fully adjusted<sup>1</sup> OR: 1.16 (1.09-1.24), Non-severe cases: all crude<sup>1</sup> OR: 1.16 (1.10-1.21), All fully adjusted OR: 1.13 (1.08-1.19), Men crude<sup>1</sup> OR: 1.15 (1.07-1.23), Men fully adjusted OR: 1.15 (1.07-1.23), Women crude<sup>1</sup> OR: 0.99 (0.92-1.08), Women fully adjusted OR: 1.01 (0.94-1.08) | | | |
|                     |         |     |            |                   |               |                |            | Non-severe cases: all crude<sup>1</sup> OR: 1.08 (1.03-1.14), All fully adjusted<sup>1</sup> OR: 1.07 (1.02-1.13), Men crude<sup>1</sup> OR: 1.08 (1.03-1.14), Men fully adjusted<sup>1</sup> OR: 1.10 (1.02-1.13), Women crude<sup>1</sup> OR: 1.01 (0.94-1.08), Women fully adjusted<sup>1</sup> OR: 1.01 (0.94-1.08), Non-severe cases: all crude<sup>1</sup> OR: 1.02 (0.97-1.08), All fully adjusted<sup>1</sup> OR: 1.00 (0.94-1.06), Men crude<sup>1</sup> OR: 1.09 (1.01-1.19), Men fully adjusted<sup>1</sup> OR: 1.06 (0.98-1.16), Women crude<sup>1</sup> OR: 0.96 (0.89-1.04), Women fully adjusted<sup>1</sup> OR: 0.95 (0.88-1.02), Severe cases: all crude<sup>1</sup> OR: 1.32 (1.19-1.47), All fully adjusted<sup>1</sup> OR: 1.19 (1.07-1.33), Men crude<sup>1</sup> OR: 1.32 (1.11-1.56), Men fully adjusted<sup>1</sup> OR: 1.20 (1.01-1.43), Women crude<sup>1</sup> OR: 1.33 (1.15-1.53), Women fully adjusted<sup>1</sup> OR: 1.19 (1.03-1.37) | | | |

Table S6 (Continued)
| Study | Study design and Period | Setting | Age, sample size (proportion of males) | Diagnosis of AD | Outcome definition | Statistical analysis | CAD | Angina | MI | HF | Stroke |
|-------|-------------------------|---------|---------------------------------------|----------------|--------------------|---------------------|------|--------|----|----|--------|
|       |                         |         |                                       |                |                    |                     |      | adjusted OR: 1.12 (1.04-1.20), Women crude OR: 1.17 (1.09-1.25), Women fully adjusted OR: 1.15 (1.08-1.24), Severe cases: all crude OR: 1.27 (1.15-1.40), All fully adjusted OR: 1.11 (1.00-1.24), Men crude OR: 1.16 (1.00-1.34), Men fully adjusted OR: 1.04 (0.89-1.21), Women crude OR: 1.38 (1.20-1.57), Women fully adjusted OR: 1.19 (1.04-1.37) |      |         |     |     |        |

**CVD main results**

- **CAD**
  - Adjusted OR: 0.98 (0.91-1.07), Severe cases: all crude OR: 1.14 (1.03-1.27), All fully adjusted OR: 1.03 (0.92-1.15), Men crude OR: 1.09 (0.94-1.26), Men fully adjusted OR: 1.01 (0.87-1.18), Women crude OR: 1.20 (1.03-1.40), Women fully adjusted OR: 1.06 (0.91-1.24)
| Reference | Type | Country | Age | Total | AD | ICD-10 Codes | Cox Regression | Adjusted HR | Crude OR | Adjusted OR | Crude OR | Adjusted OR | Other Adjusted OR | Other Adjusted OR |
|-----------|------|---------|-----|-------|----|--------------|---------------|-------------|---------|------------|---------|------------|-----------------|-----------------|
| Jung, 2021 | Cohort | Korea | Total: 2,780,356 (49.6%), AD: 285,468 | ICD-10: one of the AD diagnostic codes and underwent two AD-related tests | prescribed medication ≥2 times (outpatient) or ≥1 time hospitalized, ICD-10 codes | Cox regression | Adjusted HR: 5.99 (4.96-7.25), Mild: 2.88 (1.07-7.75), Mod: 6.49 (1.61-26.18), Severe: 6.16 (5.0-7.47) | | | | | | | |
| Kwa 2017 | Cross-sectional | USA | ≥18 yrs, Total: 726,1487, AD-E | ICD-9 codes | Pre-coded by Association for Healthcare Research and Quality (AHRQ) | Logistic regression | Crude OR: 0.75 (0.74-0.77), Propensity OR: 0.67 (0.66-0.69) | | | | | | | |
| Nishida, 2019 | Cohort | Japan | Aged 40-79 yrs, Total: 85,099 (41.7%) | ICD-10 codes | self-reported | Cox proportional hazard regression | Frequency of Eczema: Often/Seldom or Sometimes: Adjusted HR: 1.39 (1.12-1.72), MV-adjusted HR: 1.30 (1.05-1.61) | | | | | | | |
| Radtke, 2016 | Cross-sectional | Germany | ≥18 yrs, Total: 134,957, AD: 48,140 | ICD-10 codes | ICD-10 codes | Chi-square | Ischemic heart disease: Prevalence rate: (with/without AD): 0.83 (0.80-0.86) | | | | | | | |

Table S6 (Continued)
| Study | Study design and Period | Setting | Age, sample size (proportion of males) | Study design and Period | Setting | Age, sample size (proportion of males) | Diagnosis of AD | Outcome definition | Statistical analysis | CVD main results |
|-------|------------------------|---------|----------------------------------------|------------------------|---------|----------------------------------------|----------------|-------------------|-------------------|------------------|
| Rhee, 2021<sup>10</sup> | Cohort, (2009-2018) | Korea | ≥20 yrs, Total: 9548939, AD: 18557 (48.6%) | Rhee, 2021 | Cohort, (2009-2018) | Korea | ≥20 yrs, Total: 9548939, AD: 18557 (48.6%) | ICD-10 code, ≥3 times of physician diagnosis within 1 year | ICD-10 codes | Cox proportional hazards regression | CAD: Unadjusted HR: 1.51 (1.40-1.63), Adjusted<sup>16</sup> HR: 1.21 (1.12-1.31), MV-adjusted<sup>17</sup> HR: 1.14 (1.06-1.24) |
| Riis, 2016<sup>11</sup> | Cohort, (1977-2013) | Denmark | Danish born 1947-1977, Total 53210, AD: 4814 (45%) | Riis, 2016 | Cohort, (1977-2013) | Denmark | Danish born 1947-1977, Total 53210, AD: 4814 (45%) | Two clinical diagnoses of ICD-8 or ICD-10 codes | Clinical diagnoses of ICD-8 or ICD-10 codes | Cox proportional hazards regression | CAD: Crude HR: all: 1.79 (1.25-2.57), Men: 2.03 (1.32-3.12), Women: 1.39 (0.72-2.69), Mild: 1.62 (1.04-2.51), Severe: 2.38 (1.26-4.50), Adjusted<sup>18</sup> HR: 1.74 (1.21-2.49); Men: 2.01 (1.31-3.08), Women: 1.28 (0.66-2.48), Mild: 1.38 (1.02-2.45); Severe: 2.40 (1.27-4.45) |
| Shalom, 2019<sup>12</sup> | Cross-sectional, (1998-2016) | Israel | AD: 116816 patients (2.7% of total), Control: 116812 | Shalom, 2019 | Cross-sectional, (1998-2016) | Israel | AD: 116816 patients (2.7% of total), Control: 116812 | At least one documented diagnosis | “CHS Chronic Disease Register” | Logistic regression | CAD n (%): 538 (0.5) General population n (%): 572 (0.5), p=0.306 | AD n (%): 538 (0.5) General population n (%): 572 (0.5), p=0.306 |
| Reference | Study Type, (Year) | Country (Survey) | Age Range, Total (Number) | Self-reported Doctor Diagnosis | Logistic Regression Results |
|-----------|--------------------|------------------|--------------------------|-------------------------------|-----------------------------|
| Silverberg, 2015 | Cross-sectional, (2005-2006) | USA (NHANES) | ≥20 yrs, Total: 4970 (AD: 3.1% of total) | | Crude OR: 2.57 (1.45-4.53), Model 1 adjusted OR: 2.11 (1.14-3.91) Model 2 adjusted OR: 2.46 (1.37-4.43) Model 3 adjusted OR: 1.96 (1.02-3.77) |
| | | | | | Crude OR: 1.87 (0.98-3.57), Model 1 adjusted OR: 1.63 (0.84-3.15) Model 2 adjusted OR: 1.91 (0.98-3.69) Model 3 adjusted OR: 1.35 (0.55-3.28) |
| | | | | | Crude OR: 2.59 (1.35-4.96), Model 1 adjusted OR: 2.33 (1.22-4.46) Model 2 adjusted OR: 2.58 (1.31-5.06) Model 3 adjusted OR: 1.98 (0.96-4.12) |
| | | | | | Crude OR: 2.37 (1.27-4.41), Model 1 adjusted OR: 2.01 (1.03-3.94) Model 2 adjusted OR: 2.25 (1.17-4.32) Model 3 adjusted OR: 1.90 (0.96-3.77) |
| | | | | | Crude OR: 0.76 (0.31-1.86), Model 1 adjusted OR: 0.71 (0.29-1.74) Model 2 adjusted OR: 0.74 (0.30-1.82) Model 3 adjusted OR: 0.61 (0.21-1.80) |
| | Cross-sectional, (2010) | USA (NHIS) | ≥18 yrs, Total: 27157 (AD: 10.2% of total) | | Crude OR: 1.48 (1.22-1.80), Model 1 adjusted OR: 1.38 (1.13-1.69) Model 2 adjusted OR: 1.41 (1.16-1.71) Model 3 adjusted OR: 1.38 (1.12-1.70) |
| | | | | | Crude OR: 1.87 (1.44-2.42), Model 1 adjusted OR: 1.79 (1.37-2.35) Model 2 adjusted OR: 1.58 (1.21-2.05) Model 3 adjusted OR: 1.73 (1.30-2.31) |
| | | | | | Crude OR: 1.73 (1.39-2.16), Model 1 adjusted OR: 1.72 (1.36-2.17) Model 2 adjusted OR: 1.65 (1.32-2.06) Model 3 adjusted OR: 1.48 (1.15-1.90) |
| | | | | | Crude OR: 1.61 (1.27-2.05), Model 1 adjusted OR: 1.61 (1.25-2.07) Model 2 adjusted OR: 1.53 (1.19-1.96) Model 3 adjusted OR: 1.39 (1.05-1.83) |
| | Cross-sectional, (2012) | USA (NHIS) | ≥18 yrs, Total: 34525 (AD: 7.2% of total) | | Crude OR: 1.36 (1.09-1.69), Model 1 adjusted OR: 1.50 (1.18-1.90) Model 2 adjusted OR: 1.31 (1.06-1.64) Model 3 adjusted OR: 1.32 (1.04-1.66) |
| | | | | | Crude OR: 1.73 (1.18-2.54), Model 1 adjusted OR: 1.81 (1.21-2.70) Model 2 adjusted OR: 1.58 (1.09-2.30) Model 3 adjusted OR: 1.77 (1.20-2.61) |
| | | | | | Crude OR: 1.33 (1.03-1.70), Model 1 adjusted OR: 1.44 (1.11-1.87) Model 2 adjusted OR: 1.29 (1.01-1.66) Model 3 adjusted OR: 1.26 (0.96-1.64) |
| | | | | | Crude OR: 1.63 (1.27-2.09), Model 1 adjusted OR: 1.75 (1.35-2.28) Model 2 adjusted OR: 1.52 (1.19-1.95) Model 3 adjusted OR: 1.73 (1.33-2.25) |

Table S6 (Continued)
| Study | Study design and Period | Setting | Age, sample size (proportion of males) | Diagnosis of AD | Outcome definition | Statistical analysis | CAD | Angina | MI | HF | Stroke |
|-------|-------------------------|---------|---------------------------------------|-----------------|--------------------|---------------------|-----|--------|----|----|--------|
| Silverwood, 2018 | Cohort, (1998-2015) | UK | ≥18 yrs, AD: 38,7439 (36.1%) Match group: 152,847 | At least one diagnosis code and two treatment codes on separate dates, ICD-10 codes | ICD-9 or ICD-10 codes | Cox regression | (Unstable angina) | Unadjusted: HR: 1.22 (1.14-1.31) Mild: 1.22 (1.11-1.33) Mod: 1.20 (1.08-1.34) Severe: 1.47 (1.10-1.97) Adjusted: HR: 1.25 (1.11-1.41) Mild: 1.25 (1.10-1.43) Mod: 1.22 (1.06-1.42) Severe: 1.48 (1.08-2.03) Mediation model: HR: 1.17 (1.03-1.32) Mild: 1.19 (1.04-1.37) Mod: 1.11 (0.96-1.29) Severe: 1.41 (1.02-1.95) | Unadjusted: HR: 1.10 (1.05-1.15) Mild: 1.03 (0.96-1.09) Mod: 1.15 (1.07-1.23) Severe: 1.46 (1.21-1.74) Adjusted*: HR: 1.06 (0.98-1.15) Mild: 1.00 (0.91-1.10) Mod: 1.11 (1.01-1.23) Severe: 1.41 (1.15-1.71) Mediation model: HR: 1.04 (0.96-1.13) Mild: 1.00 (0.91-1.10) Mod: 1.07 (0.97-1.18) Severe: 1.37 (1.12-1.68) | Unadjusted: HR: 1.21 (1.16-1.26) Mild: 1.12 (1.05-1.19) Mod: 1.27 (1.19-1.35) Severe: 1.71 (1.43-2.05) Adjusted*: HR: 1.19 (1.10-1.30) Mild: 1.12 (1.02-1.23) Mod: 1.25 (1.14-1.38) Severe: 1.69 (1.38-2.06) Mediation model: HR: 1.17 (1.08-1.28) Mild: 1.12 (1.02-1.24) Mod: 1.20 (1.09-1.33) Severe: 1.67 (1.36-2.05) | Unadjusted: HR: 1.07 (1.03-1.12) Mild: 1.03 (0.98-1.09) Mod: 1.11 (1.04-1.18) Severe: 1.19 (1.00-1.42) Adjusted*: HR: 1.10 (1.02-1.19) Mild: 1.07 (0.98-1.16) Mod: 1.14 (1.04-1.25) Severe: 1.22 (1.01-1.48) Mediation model: HR: 1.08 (1.00-1.16) Mild: 1.06 (0.97-1.15) Mod: 1.09 (1.00-1.20) Severe: 1.20 (0.99-1.46) |
| Study | Design | Country (Healthcare System) | Age | Total | AD | ICD-10 codes | Method | RR/HR (95% CI) |
|-------|--------|-----------------------------|-----|-------|----|--------------|--------|----------------|
| Standl, 2017 | Cross-sectional, (2012-2014) | Germany (AOK PLUS) | ≥40 yrs | Total: 1180678 | AD: 36606 (36.24%) | At least two clinical diagnoses of ICD-10 codes | Linear regression | Model 1 adjusted: RR: All: 1.34 (1.28-1.41), Mild: 1.20 (1.10-1.31), Mod: 1.33 (1.25-1.42), Severe: 1.60 (1.45-1.77), Model 2 Adjusted: RR: All: 1.32 (1.26-1.38), Mild: 1.18 (1.08-1.29), Mod: 1.31 (1.23-1.39), Severe: 1.57 (1.43-1.74) |
| | | | | | | | | Model 2 Adjusted: RR: All: 0.98 (0.91-1.06), Mild: 0.95 (0.82-1.09), Mod: 0.95 (0.86-1.06), Severe: 1.12 (0.94-1.33) |
| | Cohort, (2005-2014) | Germany (AOK PLUS) | ≥40 yrs | Total: 121413 | AD: 33816 (35%) | At least two clinical diagnoses of ICD-10 codes | Linear regression | Model 1 adjusted: RR: All: 1.18 (1.13-1.23), Mild: 0.94 (0.85-1.04), Mod: 1.21 (1.13-1.29), Severe: 1.38 (1.26-1.50), Model 2 Adjusted: RR: All: 1.17 (1.12-1.23), Mild: 0.93 (0.84-1.03), Mod: 1.20 (1.12-1.28), Severe: 1.37 (1.25-1.49) |
| | | | | | | | | Model 1 adjusted: RR: All: 1.05 (0.98-1.12), Mild: 0.91 (0.79-1.04), Mod: 1.10 (1.01-1.20), Severe: 1.07 (0.94-1.22), Model 2 Adjusted: RR: All: 1.05 (0.99-1.12), Mild: 0.92 (0.80-1.05), Mod: 1.11 (1.02-1.21), Severe: 1.08 (0.95-1.22) |
| Su, 2014 | Cohort, (2005-2009) | Taiwan | ≥20 yrs | Total: 40646 | AD: 20323 (38.1%) | ICD-9 codes (newly diagnosed) | Cox's proportional hazard regression | Adjusted HR: 1.31 (0.88-1.95) |
| | | | | | | | | Adjusted HR: 1.46 (1.10-1.93) |
| | | | | | | | | [Ischemic stroke] Crude HR: 1.29 (1.09-1.54), Adjusted HR: 1.33 (1.12-1.59) |

Table S6 (Continued)
## CVD main results

| Study | Study design and Period | Setting | Age, sample size (proportion of males) | Diagnosis of AD | Outcome definition | Statistical analysis | CAD | Angina | MI | HF | Stroke |
|-------|-------------------------|---------|---------------------------------------|-----------------|-------------------|---------------------|-----|--------|-----|-----|--------|
| Sung, 2017<sup>17</sup> | Cohorts, (2000-2011) | Taiwan | Total: 75,515, AD: 15,103 (45.8%) | Outpatients received at least three consensus diagnoses, ICD-9 codes | Brain computed tomography or magnetic resonance imaging and at least three consensus diagnosis | Cox’ proportional hazard regression |       |        |     |     |        |
|        |                         |         | Crude HR: All stroke: 1.25 (1.13-1.39), Ischemic stroke: 1.30 (1.17-1.46), Hemorrhagic stroke: 1.00 (0.76-1.32), Adjusted<sup>2</sup> HR: 1.17 (1.06-1.30), Ischemic stroke: 1.21 (1.08-1.36), Hemorrhagic stroke: 0.97 (0.74-1.29) |
| Trendler, 2017<sup>18</sup> | Cross-sectional, (2011-2014) | Germany | Logistic regression: Total: 43,40, AD: 168 | Physician-diagnosed AD (ever) | Physician diagnosis | Logistic regression | OR: 1.6 (0.8-3.0) | OR: 0.5 (0.2-1.6) | OR: 1.3 (0.6-2.9) |
| Tsai, 2016<sup>19</sup> | Cohort (2000-2011) | Taiwan | ≥20 yrs. Total: 47,044, AD: 23,522 (41.87%) | ICD-9 codes, (at least two medical visits) | New diagnosis of stroke, ICD-9 codes | Cox’s proportional hazard regression | Stroke: Crude HR: 1.27 (1.23-1.3), Adjusted<sup>3</sup> HR: 1.13 (1.10-1.16), Ischemic stroke: 1.30 (1.27-1.34), Adjusted<sup>4</sup> HR: 1.16 (1.12-1.19) |
| Varbo, 2017<sup>20</sup> | Cohort, (2003-2014) | Denmark | Total: 84,601, AD: 8,484 | self-reported | ICD-8 ICD-10 codes (two independent doctors) | Cox proportional hazard regression | Ischemic stroke: Adjusted<sup>5</sup> HR: 1.24 (1.01-1.52), MV-adjusted<sup>6</sup> HR: 1.19 (0.96-1.48) |

AD: atopic dermatitis, CVD: cardiovascular disease, CAD: coronary artery disease, MI: myocardial infarction, HF: heart failure, yrs: years old, ICD: International Classification of Diseases, RR: incident rate ratios, OR: odds ratio, HR: hazard ratio, RR: risk ratio. MV: multivariate, BMI: body mass index

<sup>1</sup> Adjusted for age and sex
<sup>2</sup> Adjusted for age and sex, socioeconomic status, smoking, comorbidities, and medication use
<sup>3</sup> Adjusted for age
<sup>4</sup> Adjusted for age, race, BMI, physical activity, alcohol, smoking, family history of MI, hormone replacement use
<sup>5</sup> Adjusted for age, race, BMI, physical activity, alcohol, smoking, family history of MI, hormone replacement use, history of hypertension, hypercholesterolemia and diabetes
1. Adjusted for age and sex

2. Adjusted for age, sex, ethnic background, body mass index, smoking 100 cigarettes, weekly alcohol intake, average daily sleep, weekly physical activity and history of asthma

3. The analysis for each outcome is additionally adjusted for all three other outcomes (hypertension, type 2 diabetes, MI, stroke)

4. Adjusted for age, sex, socioeconomic status, and number of dermatology visits

5. Adjusted for age and sex

6. Adjusted for cardiovascular comorbidities (diabetes mellitus, hyperlipidemia, hypertension) and years of education

7. Adjusted for sex, age, and other CVD and metabolic diseases

8. Adjusted for age, sex, race, mean annual household income, insurance status, number of chronic conditions, and hospital region

9. Adjusted for age and sex

10. Adjusted for age, sex, BMI, history of hypertension, diabetes, alcohol, smoking, perceived mental stress, daily walking time, participation in sports, sleep duration, education

11. Adjusted for age and sex

12. Adjusted for age and sex, smoking, alcohol, physical activity, low socioeconomic status, BMI, hypertension, diabetes mellitus, and dyslipidemia

13. Adjusted for birth-year categories, gender, educational level and history of diabetes, hypertension, hyperlipidaemia or stroke

14. Adjusted for age, highest level of education in the household, ethnicity, and sex

15. Adjusted for 1-year history of asthma and hay fever

16. Adjusted for BMI, history of ever smoking cigarettes, consumption of alcohol in the past year, and vigorous activity in the past 30 days

17. Adjusted for BMI, history of ever smoking cigarettes, consumption of alcohol in the past year, and vigorous activity in the past week

18. Adjusted for current calendar period (1997-99, 2000-04, 2005-09, 2010-15), time since diagnosis (0-4, 5-9, 10-14, 15-19, ≥20 years), index of multiple deprivation at cohort entry, and time-varying asthma

19. Adjusted additionally for BMI and smoking at cohort entry, and time-varying hyperlipidaemia, hypertension, depression, anxiety, diabetes, and severe alcohol use

20. Adjusted for sex and cubic age

21. Adjusted for sex, cubic age, and socioeconomic status of region and access to health care

22. Adjusted for age, sex, comorbidities and medication

23. Adjusted for AD, age, sex, and comorbidity

24. Adjusted for age, gender, treatment, and comorbidity

25. Adjusted for age and sex

26. Adjusted for age, sex, smoking, lipid-lowering therapy, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, diabetes, alcohol consumption, systolic and diastolic blood pressure, BMI, physical activity, atrial fibrillation
Figure 1. Scatter plot for Mendelian randomization analysis for AD on stroke.

Figure 2. Scatter plot for Mendelian randomization analysis for AD on heart failure.
Figure 3. Scatter plot for Mendelian randomization analysis for AD on CAD.

Figure 4. Scatter plot for Mendelian randomization analysis for AD on myocardial infarction.
Figure 5. Scatter plot for Mendelian randomization analysis for AD on angina pectoris.

References

1. Andersen YMF, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. The Journal of allergy and clinical immunology. 2016;138(1) doi:10.1016/j.jaci.2016.01.015

2. Drucker AM, Li WQ, Cho E, et al. Atopic dermatitis is not independently associated with nonfatal myocardial infarction or stroke among US women. Allergy. 2016;71(10):1496–1500. doi:10.1111/all.12957

3. Drucker AM, Qureshi AA, Dummer TJB, Parker L, Li WQ. Atopic dermatitis and risk of hypertension, type 2 diabetes, myocardial infarction and stroke in a cross-sectional analysis from the Canadian Partnership for Tomorrow Project. The British journal of dermatology. 2017;177(4):1043–1051. doi:10.1111/bjd.15727

4. Egeberg A, Andersen YMF, Gislason GH, Skov L, Thyssen JP. Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis. Allergy. 2017;72(5):783–791. doi:10.1111/all.13085

5. Ivert LU, Johansson EK, Dal H, Lindelof B, Wahlgren C-F, Bradley M. Association Between Atopic Dermatitis and Cardiovascular Disease: A Nationwide Register-based Case-control Study from Sweden. Acta dermato-venereologica. 2019;99(10):865–870. doi:10.2340/00015555-3235

6. Jung HJ, Lee DH, Park MY, Ahn J. Cardiovascular comorbidities of atopic dermatitis: using National Health Insurance data in Korea. Allergy Asthma Clin Immunol. 2021;17(1):94. doi:10.1186/s13223-021-00590-x

7. Kwa MC, Silverberg JI. Association Between Inflammatory Skin Disease and Cardiovascular and Cerebrovascular Co-Morbidities in US Adults: Analysis of Nationwide Inpatient Sample Data. American journal of clinical dermatology. 2017;18(6):813–823. doi:10.1007/s40257-017-0293-x

8. Nishida Y, Kubota Y, Iso H, Tamakoshi A. Self-Reported Eczema in Relation with Mortality from Cardiovascular Disease in Japanese: the Japan Collaborative Cohort Study. J Atheroscler Thromb. 2019;26(9):775–782. doi:10.5551/jat.46383

9. Radtke MA, Schafer I, Glaseke G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. Jan 2017;31(1):151–157. doi:10.1111/jdv.13813

10. Rhee T-M, Choi E-K, Han K-D, Lee S-R, Oh S. Impact of the Combinations of Allergic Diseases on Myocardial Infarction and Mortality. The journal of allergy and clinical immunology In practice. 2021;9(2)doi:10.1016/j.jaip.2020.09.008

11. Riis JL, Vestergaard G, Hjuler KE, et al. Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study. BMJ Open. Nov 11 2016;6(11):e011870. doi:10.1136/bmjopen-2016-011870

12. Shalom G, Dreher J, Kridin K, et al. Atopic dermatitis and the metabolic syndrome: a cross-sectional study of 116 816 patients. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019;33(9):1762–1767. doi:10.1111/jdv.15642

13. Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy. 2015;70(10):1300–1308. doi:10.1111/all.12685
14. Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ (Clinical research ed). 2018;361:k1786. doi:10.1136/bmj.k1786

15. Standl M, Tesch F, Baurecht H, et al. Association of Atopic Dermatitis with Cardiovascular Risk Factors and Diseases. The Journal of Investigative Dermatology. 2017;137(5):1074–1081. doi:10.1016/j.jid.2016.11.031

16. Su VY-F, Chen T-J, Yeh C-M, et al. Atopic dermatitis and risk of ischemic stroke: a nationwide population-based study. Ann Med. 2014;46(2):84–89. doi:10.3109/07853890.2013.870018

17. Lee J-T, Chien W-C, Sung Y-F, et al. Increased risk of stroke in patients with atopic dermatitis: A population-based, longitudinal study in Taiwan. Journal of Medical Sciences. 2017;37(1) doi:10.4103/1011-4564.200737

18. Treudler R, Zeynalova S, Walther F, Engel C, Simon JC. Atopic dermatitis is associated with autoimmune but not with cardiovascular comorbidities in a random sample of the general population in Leipzig, Germany. Journal of the European Academy of Dermatology and Venereology: JEADV. 2018;32(2):e44–e46. doi:10.1111/jdv.14495

19. Tsai K-S, Yen C-S, Wu P-Y, et al. Traditional Chinese Medicine Decreases the Stroke Risk of Systemic Corticosteroid Treatment in Dermatitis: A Nationwide Population-Based Study. Evid Based Complement Alternat Med. 2015;2015:543517. doi:10.1155/2015/543517

20. Varbo A, Nordestgaard BG, Benn M. Filaggrin loss-of-function mutations as risk factors for ischemic stroke in the general population. J Thromb Haemost. 2017;15(4):624–635. doi:10.1111/jth.13644